Cardiovascular gene therapy for myocardial infarction

Scimia, Maria Cecilia; Gumpert, Anna M.; Koch, Walter J.

doi:10.1517/14712598.2014.866085

Cited by 51 publications

(35 citation statements)

References 134 publications

(137 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although clinical treatment continues to be improved over the past decades, the pandemic continues to show an upward trend [18]. Recently, due to increased insight into the molecular mechanisms of cardiovascular diseases, gene therapy has been proposed as a promising therapeutic tool for MI [19]. In this study, CD151 delivery was revealed to be beneficial as a treatment of MI, and US microbubble was able to improve its delivery efficiency.…”

Section: Discussionmentioning

confidence: 88%

Delivery of CD151 by Ultrasound Microbubbles in Rabbit Myocardial Infarction

Yang

Tang²,

Tao³

et al. 2016

Cardiology

View full text Add to dashboard Cite

Objectives: We aimed to evaluate whether ultrasound (US) and microbubble-mediated delivery of Cluster of Differentiation 151 (CD151) could enhance the therapeutic effects of CD151 on myocardial infarction (MI). Methods: A rabbit model of MI was established by a modified Fujita method. Then, 50 MI rabbits were randomly divided into 5 groups, including G1 (CD151 plasmid and physiological saline in the presence of US); G2 (CD151 and Sonovue in the presence of US); G3 (CD151 and Sonovue in the absence of US); G4 (Sonovue in the absence of US), and a control group (physiological saline in the absence of US). After 14 days of treatment, the expression of CD151 was detected by Western blot. Besides, vessel density of peri-infarcted myocardium was measured by immunohistochemistry, and cardiac function was analyzed by echocardiography. Results: The rabbit model of MI was established successfully. CD151 injection increased the expression of CD151 and microvessel density in the myocardium of MI rabbits. Heart function was significantly improved by CD151, which exhibited increased left ventricular ejection fraction, left ventricular fractional shortening and a reduced Tei index. Besides, US Sonovue significantly increased the expression efficiency of CD151. Conclusion: US microbubble was an effective vector for CD151 delivery. CD151 might be an effective therapeutic target for MI.

show abstract

Section: Discussionmentioning

confidence: 88%

Delivery of CD151 by Ultrasound Microbubbles in Rabbit Myocardial Infarction

Yang

Tang²,

Tao³

et al. 2016

Cardiology

View full text Add to dashboard Cite

show abstract

“…For a detailed review of methods used to achieve stable cardiac-specific gene transfer, the reader is referred to excellent reviews on the subject [97, 98]. Major considerations include whether transient or chronic gene expression is needed, which specific cell type requires modification, and whether gene transfer is to be applied locally or globally.…”

Section: Expert Opinion: Gene Therapy For Arrhythmias In Hfmentioning

confidence: 99%

Gene therapy to restore electrophysiological function in heart failure

Motloch¹,

Akar²

2015

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

Introduction Heart failure (HF) is a major public health epidemic and a leading cause of morbidity and mortality in the industrialized world. Existing treatments for patients with HF are often associated with pro-arrhythmic activity and risk of sudden cardiac death (SCD). Therefore, development of novel, effective, and safe therapeutic options for HF patients is a critical area of unmet need. Areas Covered In this article, we review recent advances in the emerging field of cardiac gene therapy for the treatment of tachy- and brady- arrhythmias in HF. We provide an overview of gene-based approaches that modulate myocardial conduction, repolarization, calcium cycling, and adrenergic signaling to restore heart rate and rhythm. Expert Opinion We highlight major advantages of gene therapy for arrhythmias, including the ability to selectively target specific cell populations and to limit the therapeutic effect to the region that requires modification. We illustrate how advances in our fundamental understanding of the molecular origins of arrhythmogenic disorders are allowing investigators to use targeted gene-based approaches to successfully correct abnormal excitability in the atria, ventricles, and conduction system. Translation of various gene therapy approaches to humans may revolutionize our ability to combat lethal arrhythmias in HF patients.

show abstract

“…We focus on proteins as potential therapies to repair and regenerate damaged cardiac tissue. Gene and cell-based therapies are thoroughly reviewed elsewhere [3, 7-11]. Additionally, we focus on the complexity of tissue regeneration and repair processes and reasons for more comprehensive therapies.…”

Section: Introductionmentioning

confidence: 99%

Towards comprehensive cardiac repair and regeneration after myocardial infarction: Aspects to consider and proteins to deliver

2016

View full text Add to dashboard Cite

Ischemic heart disease is a leading cause of death worldwide. After the onset of myocardial infarction, many pathological changes take place and progress the disease towards heart failure. Pathologies such as ischemia, inflammation, cardiomyocyte death, ventricular remodeling and dilation, and interstitial fibrosis, develop and involve the signaling of many proteins. Proteins can play important roles in limiting or countering pathological changes after infarction. However, they typically have short half-lives in vivo in their free form and can benefit from the advantages offered by controlled release systems to overcome their challenges. The controlled delivery of an optimal combination of proteins per their physiologic spatiotemporal cues to the infarcted myocardium holds great potential to repair and regenerate the heart. The effectiveness of therapeutic interventions depends on the elucidation of the molecular mechanisms of the cargo proteins and the spatiotemporal control of their release. It is likely that multiple proteins will provide a more comprehensive and functional recovery of the heart in a controlled release strategy.

show abstract

Cardiovascular gene therapy for myocardial infarction

Cited by 51 publications

References 134 publications

Delivery of CD151 by Ultrasound Microbubbles in Rabbit Myocardial Infarction

Delivery of CD151 by Ultrasound Microbubbles in Rabbit Myocardial Infarction

Gene therapy to restore electrophysiological function in heart failure

Towards comprehensive cardiac repair and regeneration after myocardial infarction: Aspects to consider and proteins to deliver

Contact Info

Product

Resources

About